CHEST:非小细胞肺癌I期患者行亚肺叶切除术易复发

2012-12-14 sd3212 丁香园

   目前I期非小细胞肺癌患者(NSCLC)接受亚肺叶切除手术(sublobar resection,L-)的比例越来越多。然而,有关这种手术后,患者肿瘤局部复发(LR)的风险及其与手术方式的相关性的资料却很少,尤其是接受亚肺叶切除手术者与接受肺叶切除术(L+)者在这些方面的比较资料更为少见。为了对上述资料加以补充,来自于美国宾夕法尼亚州赫希市佩恩国家癌症研究所的J. Varlotto博士

肺癌
  

目前I期非小细胞肺癌患者(NSCLC)接受亚肺叶切除手术(sublobar resection,L-)的比例越来越多。然而,有关这种手术后,患者肿瘤局部复发(LR)的风险及其与手术方式的相关性的资料却很少,尤其是接受亚肺叶切除手术者与接受肺叶切除术(L+)者在这些方面的比较资料更为少见。为了对上述资料加以补充,来自于美国宾夕法尼亚州赫希市佩恩国家癌症研究所的J. Varlotto博士及其同事进行了一项研究,研究结果在线发表于2012年11月29日的《胸部》(CHEST)杂志上。作者发现,与接受肺叶切除手术者相比,I期非小细胞肺癌患者接受亚肺叶切除手术后,其肿瘤局部复发的风险增加。这在那些肿瘤分级≥2级或肿瘤大于2厘米的患者中尤其明显。研究者建议,如果准备为I期非小细胞肺癌患者(尤其是那些肿瘤分级≥2级或肿瘤大于2厘米的患者)施行亚肺叶手术切除时,应考虑给予其额外的局部治疗以减少肿瘤局部复发的风险。

  该研究的研究对象主要为2000年~2006年间的连续性的非小细胞肺癌患者,其中有93例患者接受了亚肺叶切除手术,318例患者接受了肺叶切除手术。中位随访时间为34个月。

  该研究的主要结果为:在亚肺叶切除手术组,患者在手术后第2、3、和5年时的肿瘤局部复发率分别为13%、24%、和40%。肿瘤局部复发的风险与肿瘤分级、肿瘤大小、和肺癌的T分期明显相关。在肿瘤分级≥2级且接受亚肺叶切除手术的患者中,肿瘤局部复发的大致风险为30%(21/69)。在肺叶切除手术组,患者在手术后第2、3、和5年时的肿瘤局部复发率分别为14%、19%、和24%。肿瘤局部复发的风险随着肿瘤的增大、住院时间的延长及糖尿病的存在而显着增加。与肺叶切除手术组相比,亚肺叶切除手术组在支气管残端/缝合线处出现手术失败(肿瘤局部复发)者明显增加(10%对3%,p= 0.04),而同侧肺门及隆突下的手术失败率虽有增加的趋势,但无统计学差异。

  该研究结果显示:与接受肺叶切除手术者相比,I期非小细胞肺癌患者接受亚肺叶切除手术后,其肿瘤局部复发的风险增加。这在那些肿瘤分级≥2级或肿瘤大小大于2厘米的患者中尤其明显。研究者建议,如果准备为I期非小细胞肺癌患者(尤其是那些肿瘤分级≥2级或肿瘤大于2厘米的患者)施行亚肺叶手术切除时,应考虑给予其额外的局部治疗以减少肿瘤局部复发的风险。

原始链接:

Donington J, Ferguson M, Mazzone P, Handy J Jr, Schuchert M, Fernando H, Loo B, Lanuti M, de Hoyos A, Detterbeck F, Pennathur A, Howington J, Landreneau R, Silvestri G.American College of Chest Physicians and Society of Thoracic Surgeons Consensus Statement for Evaluation and Management for High-Risk Patients With Stage I Non-small Cell Lung Cancer.Chest. 2012 Dec;142(6):1620-35.

  



    

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1929159, encodeId=143b1929159d0, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Sat Aug 10 17:41:00 CST 2013, time=2013-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1987776, encodeId=559d198e7768d, content=<a href='/topic/show?id=93d8243089c' target=_blank style='color:#2F92EE;'>#亚肺叶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24308, encryptionId=93d8243089c, topicName=亚肺叶)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f984116, createdName=kzlchina, createdTime=Wed Aug 07 19:41:00 CST 2013, time=2013-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2059423, encodeId=fb8c205942398, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Mon Apr 01 04:41:00 CST 2013, time=2013-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050330, encodeId=c8092050330a6, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Mon Mar 11 14:41:00 CST 2013, time=2013-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1876629, encodeId=47a018e66290d, content=<a href='/topic/show?id=67c5319121e' target=_blank style='color:#2F92EE;'>#切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31912, encryptionId=67c5319121e, topicName=切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Wed Jul 31 22:41:00 CST 2013, time=2013-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1556419, encodeId=8a7d1556419c2, content=<a href='/topic/show?id=a9b0820898c' target=_blank style='color:#2F92EE;'>#肺叶切除#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82089, encryptionId=a9b0820898c, topicName=肺叶切除)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=727d14772225, createdName=zhangj7113, createdTime=Sun Dec 16 08:41:00 CST 2012, time=2012-12-16, status=1, ipAttribution=)]
    2013-08-10 Smile2680
  2. [GetPortalCommentsPageByObjectIdResponse(id=1929159, encodeId=143b1929159d0, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Sat Aug 10 17:41:00 CST 2013, time=2013-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1987776, encodeId=559d198e7768d, content=<a href='/topic/show?id=93d8243089c' target=_blank style='color:#2F92EE;'>#亚肺叶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24308, encryptionId=93d8243089c, topicName=亚肺叶)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f984116, createdName=kzlchina, createdTime=Wed Aug 07 19:41:00 CST 2013, time=2013-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2059423, encodeId=fb8c205942398, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Mon Apr 01 04:41:00 CST 2013, time=2013-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050330, encodeId=c8092050330a6, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Mon Mar 11 14:41:00 CST 2013, time=2013-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1876629, encodeId=47a018e66290d, content=<a href='/topic/show?id=67c5319121e' target=_blank style='color:#2F92EE;'>#切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31912, encryptionId=67c5319121e, topicName=切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Wed Jul 31 22:41:00 CST 2013, time=2013-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1556419, encodeId=8a7d1556419c2, content=<a href='/topic/show?id=a9b0820898c' target=_blank style='color:#2F92EE;'>#肺叶切除#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82089, encryptionId=a9b0820898c, topicName=肺叶切除)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=727d14772225, createdName=zhangj7113, createdTime=Sun Dec 16 08:41:00 CST 2012, time=2012-12-16, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1929159, encodeId=143b1929159d0, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Sat Aug 10 17:41:00 CST 2013, time=2013-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1987776, encodeId=559d198e7768d, content=<a href='/topic/show?id=93d8243089c' target=_blank style='color:#2F92EE;'>#亚肺叶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24308, encryptionId=93d8243089c, topicName=亚肺叶)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f984116, createdName=kzlchina, createdTime=Wed Aug 07 19:41:00 CST 2013, time=2013-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2059423, encodeId=fb8c205942398, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Mon Apr 01 04:41:00 CST 2013, time=2013-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050330, encodeId=c8092050330a6, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Mon Mar 11 14:41:00 CST 2013, time=2013-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1876629, encodeId=47a018e66290d, content=<a href='/topic/show?id=67c5319121e' target=_blank style='color:#2F92EE;'>#切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31912, encryptionId=67c5319121e, topicName=切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Wed Jul 31 22:41:00 CST 2013, time=2013-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1556419, encodeId=8a7d1556419c2, content=<a href='/topic/show?id=a9b0820898c' target=_blank style='color:#2F92EE;'>#肺叶切除#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82089, encryptionId=a9b0820898c, topicName=肺叶切除)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=727d14772225, createdName=zhangj7113, createdTime=Sun Dec 16 08:41:00 CST 2012, time=2012-12-16, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1929159, encodeId=143b1929159d0, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Sat Aug 10 17:41:00 CST 2013, time=2013-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1987776, encodeId=559d198e7768d, content=<a href='/topic/show?id=93d8243089c' target=_blank style='color:#2F92EE;'>#亚肺叶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24308, encryptionId=93d8243089c, topicName=亚肺叶)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f984116, createdName=kzlchina, createdTime=Wed Aug 07 19:41:00 CST 2013, time=2013-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2059423, encodeId=fb8c205942398, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Mon Apr 01 04:41:00 CST 2013, time=2013-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050330, encodeId=c8092050330a6, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Mon Mar 11 14:41:00 CST 2013, time=2013-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1876629, encodeId=47a018e66290d, content=<a href='/topic/show?id=67c5319121e' target=_blank style='color:#2F92EE;'>#切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31912, encryptionId=67c5319121e, topicName=切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Wed Jul 31 22:41:00 CST 2013, time=2013-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1556419, encodeId=8a7d1556419c2, content=<a href='/topic/show?id=a9b0820898c' target=_blank style='color:#2F92EE;'>#肺叶切除#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82089, encryptionId=a9b0820898c, topicName=肺叶切除)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=727d14772225, createdName=zhangj7113, createdTime=Sun Dec 16 08:41:00 CST 2012, time=2012-12-16, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1929159, encodeId=143b1929159d0, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Sat Aug 10 17:41:00 CST 2013, time=2013-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1987776, encodeId=559d198e7768d, content=<a href='/topic/show?id=93d8243089c' target=_blank style='color:#2F92EE;'>#亚肺叶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24308, encryptionId=93d8243089c, topicName=亚肺叶)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f984116, createdName=kzlchina, createdTime=Wed Aug 07 19:41:00 CST 2013, time=2013-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2059423, encodeId=fb8c205942398, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Mon Apr 01 04:41:00 CST 2013, time=2013-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050330, encodeId=c8092050330a6, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Mon Mar 11 14:41:00 CST 2013, time=2013-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1876629, encodeId=47a018e66290d, content=<a href='/topic/show?id=67c5319121e' target=_blank style='color:#2F92EE;'>#切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31912, encryptionId=67c5319121e, topicName=切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Wed Jul 31 22:41:00 CST 2013, time=2013-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1556419, encodeId=8a7d1556419c2, content=<a href='/topic/show?id=a9b0820898c' target=_blank style='color:#2F92EE;'>#肺叶切除#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82089, encryptionId=a9b0820898c, topicName=肺叶切除)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=727d14772225, createdName=zhangj7113, createdTime=Sun Dec 16 08:41:00 CST 2012, time=2012-12-16, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1929159, encodeId=143b1929159d0, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Sat Aug 10 17:41:00 CST 2013, time=2013-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1987776, encodeId=559d198e7768d, content=<a href='/topic/show?id=93d8243089c' target=_blank style='color:#2F92EE;'>#亚肺叶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24308, encryptionId=93d8243089c, topicName=亚肺叶)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f984116, createdName=kzlchina, createdTime=Wed Aug 07 19:41:00 CST 2013, time=2013-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2059423, encodeId=fb8c205942398, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Mon Apr 01 04:41:00 CST 2013, time=2013-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050330, encodeId=c8092050330a6, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Mon Mar 11 14:41:00 CST 2013, time=2013-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1876629, encodeId=47a018e66290d, content=<a href='/topic/show?id=67c5319121e' target=_blank style='color:#2F92EE;'>#切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31912, encryptionId=67c5319121e, topicName=切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Wed Jul 31 22:41:00 CST 2013, time=2013-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1556419, encodeId=8a7d1556419c2, content=<a href='/topic/show?id=a9b0820898c' target=_blank style='color:#2F92EE;'>#肺叶切除#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82089, encryptionId=a9b0820898c, topicName=肺叶切除)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=727d14772225, createdName=zhangj7113, createdTime=Sun Dec 16 08:41:00 CST 2012, time=2012-12-16, status=1, ipAttribution=)]

相关资讯

Ann Oncol:ALK不影响培美曲塞抗晚期非小细胞肺癌效果

     《肿瘤学年鉴》(Ann Oncol)近期发表的一项研究表明,在接受培美曲塞或非铂类/培美曲塞联合治疗的晚期非小细胞肺癌(NSCLC)患者中,间变性淋巴瘤激酶(ALK)阳性和阴性患者的无进展生存期(PFS)相似。在不吸烟或有轻度吸烟史的患者中,无论ALK状态如何,一线铂类/培美曲塞治疗可能延长PFS。   ALK阳性NSCLC对crizotinib反应良好。为了确定ALK阳性

AJP:肺癌生长的关键基因:FN14基因

  近期发表于《美国病理学杂志》(The American Journal of Pathology)的一项研究表明:在肺癌 style=color:blue >非小细胞肺癌的生长和扩散中起重要作用的基因。   肺癌是全世界癌症患者死亡的首要原因,这些癌症约85%为非小细胞肺癌(NSCLC)。非小细胞肺癌患者表皮生长因子受体(EGFR)发生基因

非小细胞肺癌(NSCLC)的放疗进展

 作者:中国医学科学院肿瘤医院放疗科 王静波 王小震 惠周光 王绿化 根治性放疗证据 ·Ⅰ期NSCLC   对于无法耐受手术的早期非小细胞肺癌(NSCLC),放疗是标准治疗。 立体定向放疗(SBRT)已被广泛接受作为外周型Ⅰ期NSCLC 的首选治疗。RTOG 0236研究显示,SBRT的3年局部控制率(局控率)高达98%,中位生存期为48.1个月。 目前接受SBRT的早

王绿化:非小细胞肺癌放疗的临床热点问题

作者:中国医学科学院肿瘤医院放疗科王绿化王绿化主任医师,博士研究生导师。现任中华医学会放射肿瘤学会常委兼秘书长,中国临床肿瘤学会(CSCO)执行委员会常委兼副秘书长,中华医学会北京放射肿瘤学分会副主任委员,北京医师协会放疗专业专家委员会副主任委员,中国抗癌协会肺癌专业委员会委员,中国抗癌协会食管癌专业委员会常委。放疗是非小细胞肺癌(NSCLC)的重要治疗手段之一,超过60%的NSCLC患者在确诊后

J Thorac Oncol:局部消融治疗可使NSCLC药物治疗长期获益

       一项小规模、单中心、回顾性研究显示,局部消融治疗可使接受酪氨酸激酶抑制剂治疗出现局部恶化的非小细胞肺癌(NSCLC)患者继续从该药物中获益。该研究结果发表在12月份的《胸部肿瘤学杂志》。(J Thorac Oncol 2012 Dec)        该研究的作者为美国科罗拉多大学癌症中心的An

Clin Oncol:吉非替尼改善非小细胞肺癌预后

  我国学者近期发表于《临床肿瘤学》(Clin Oncol)杂志的一项研究表明,与全身化疗相比,吉非替尼一线治疗可延长表皮生长因子受体(EGFR)突变非小细胞肺癌患者的无进展生存期(PFS),并改善肺腺癌患者的总生存状况。   为了确定吉非替尼对既往未接受化疗的晚期非小细胞肺癌的疗效,研究者进行了一项对于随机对照临床试验的荟萃分析。研究者搜索了Medline、Embase、Cochra